S.2236 - Advancing Breakthrough Therapies for Patients Act of 2012
A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.
Loading Bill Text
Rollover any line of text to comment and/or link to it.
Mr. BENNET (for himself, Mr. HATCH, and Mr. BURR) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsCommentsClose CommentsPermalink
SECTION 1. SHORT TITLE.
SEC. 2. BREAKTHROUGH THERAPIES AND FAST TRACK PRODUCTS.
‘(1) IN GENERAL- The Secretary shall, at the request of the sponsor of a drug, expedite the development and review of such drug if the drug is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints (such as substantial treatment effects observed early in clinical development). (In this section, such a drug is referred to as a ‘breakthrough therapy’.)CommentsClose CommentsPermalink
‘(2) REQUEST FOR DESIGNATION- The sponsor of a drug may request the Secretary to designate the drug as a breakthrough therapy. A request for the designation may be made concurrently with, or at any time after, the submission of an application for the investigation of the drug under section 505(i) or section 351(a)(3) of the Public Health Service Act.CommentsClose CommentsPermalink
‘(A) IN GENERAL- Not later than 60 calendar days after the receipt of a request under paragraph (2), the Secretary shall determine whether the drug that is the subject of the request meets the criteria described in paragraph (1). If the Secretary finds that the drug meets the criteria, the Secretary shall designate the drug as a breakthrough therapy and shall take such actions as are appropriate to expedite the development and review of the application for approval of such drug.CommentsClose CommentsPermalink
‘(ii) providing timely advice to the sponsor regarding the development of the drug to ensure that the development program to gather the non-clinical and clinical data necessary for approval is as efficient as practicable;CommentsClose CommentsPermalink
‘(v) assigning a cross-disciplinary project lead for the Food and Drug Administration review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; andCommentsClose CommentsPermalink
‘(vi) taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients enrolled in the trial and the duration of the trial and considering alternatives to the traditional multi-phase, sequential development approach, designed to abbreviate, consolidate, and condense clinical trials and studies.’;CommentsClose CommentsPermalink
‘(A) GUIDANCE- Not later than 18 months after the date of enactment of the Advancing Breakthrough Therapies for Patients Act of 2012, the Secretary shall issue draft guidance on implementing the requirements with respect to breakthrough therapies, accelerated approval, and fast track products as set forth in subsections (a) through (c), as amended by the Advancing Breakthrough Therapies for Patients Act of 2012. After an opportunity for public comment and not later than 2 years after the date of enactment of the Advancing Breakthrough Therapies for Patients Act of 2012, the Secretary shall issue final guidance.CommentsClose CommentsPermalink
‘(B) AMENDED REGULATIONS- Not later than 2 years after the date of enactment of the Advancing Breakthrough Therapies for Patients Act of 2012, the Secretary shall amend the applicable regulations under title 21, Code of Federal Regulations, as may be necessary to implement the requirements under subsections (a) through (c), as amended by the Advancing Breakthrough Therapies for Patients Act of 2012.CommentsClose CommentsPermalink
‘(B) specify the actions the Secretary shall take to expedite the development and review of a breakthrough therapy pursuant to such designation under 506(a)(3), including updating good review management practices to reflect breakthrough therapies.CommentsClose CommentsPermalink
‘(g) Independent Review- Not later than 3 years after the date of enactment of this Act, the Secretary shall, in conjunction with other planned reviews, contract with an independent entity with expertise in assessing the quality, efficiency, and predictability of biopharmaceutical development and regulatory review programs to evaluate the manner by which the Food and Drug Administration has applied the processes described in the section, as amended by the Advancing Breakthrough Therapies for Patients Act of 2012, and the impact of such processes on the development and timely availability of innovative treatments for patients affected by serious or life-threatening conditions. Such evaluation shall be completed not later than 4 years after the date of enactment of the Advancing Breakthrough Therapies for Patients Act of 2012 and shall be made publicly available upon completion.CommentsClose CommentsPermalink
‘(h) Report- Beginning in fiscal year 2013, the Secretary shall annually prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, with respect to this section for the previous fiscal year--CommentsClose CommentsPermalink
‘(B) the total time from designation as a breakthrough therapy, including the total time to review and act on an application designated as a breakthrough therapy, to approval of the drug; andCommentsClose CommentsPermalink
(b) Conforming Amendments- Section 506B(e) of the Federal Food, Drug, and Cosmetic Act (